Cycloxan 1gm Injection

• Non-Hodgkin’s and Hodgkin’s lymphomas.
• Acute and chronic lymphocytic leukemia.
• Multiple Myeloma
• Breast Cancer
• Ovarian Cancer
• Nephrotic Syndrome
• Lung Cancer

Side effects are unwanted symptoms that can occur from any medical treatment. Like other medications, the Cycloxan 1gm Injection can also have adverse effects on the body, most of which resolve without the need for medical attention.

Some common side effects include:

• Hair loss
• Nausea
• Infection
• Diarrhea
• Vomiting
• Decreased white blood cell count (neutrophils)
• Myelosuppression
• Cystitis
• Microhematuria
• Decreased white blood cell count (lymphocytes)

Seek medical attention in case of any unusual or severe side effects immediately.

• Cycloxan 1gm is available in injection form and is advised to be taken as per the doctor's prescription.
• It should be administered by a doctor or experienced nurse under strict medical supervision.Taking this injection in the wrong way may give you severe side effects.
• In case of overdose, contact your healthcare provider or doctor and they will provide you with medical attention. Missing or overdosing will impact the overall health of the patients and may also have side effects. So, it is always advisable to follow the prescription of the doctor strictly.
  
  

• Cycloxan 1gm Injection is an anticancer medicine with Cyclophosphamide as an active ingredient. It is an alkylating agent that works by destroying genetic material like DNA or RNA of the cancer cells to prevent the replication of rapidly growing cancer cells.
• Cycloxan causes the DNA strands to cross-link, that stops the cells from dividing and ultimately leads to their death. As it can cause some adverse impact on the body because it affects both healthy & cancerous cells.
  
  

• Petri, M., Jones, R. J., & Brodsky, R. A. (2003). High‐dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis & Rheumatism, 48(1), 166-173.
• Motoyoshi, Y., Kaminoda, K., Saitoh, O., Hamasaki, K., Nakao, K., Ishii, N. ... & Eguchi, K. (2006). Different mechanisms for anti-tumor effects of low-and high-dose cyclophosphamide. Oncology reports, 16(1), 141-146.
• Teles, K. A., Medeiros-Souza, P., Lima, F. A. C., de Araújo, B. G., & Lima, R. A. C. (2017). Cyclophosphamide administration routine in autoimmune rheumatic diseases: a review. Revista Brasileira de Reumatologia (English Edition), 57(6), 596-604.
• De Jonge, M. E., Huitema, A. D., Rodenhuis, S., & Beijnen, J. H. (2005). Clinical pharmacokinetics of cyclophosphamide. Clinical pharmacokinetics, 44(11), 1135-1164.
• Dussan, K. B., Magder, L., Brodsky, R. A., Jones, R. J., & Petri, M. (2008). High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures. Lupus, 17(12), 1079-1085.